Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03584022 · ClinicalTrials.gov registry record · NA

Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial

A NA study of Amyloidosis and Peripheral Neuropathy, sponsored by Mayo Clinic.

Active
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT03584022 is a NA study of Amyloidosis and Peripheral Neuropathy that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03584022, a NA study of Amyloidosis and Peripheral Neuropathy, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is safety study. Subjects will be undergoing the surgical procedure of nerve biopsy. After routine surgery without grafting, patients develop swelling, redness, tenderness and dysesthesia at the biopsy site. In order to determine whether grafting is safe compared to not repairing the nerve, it is necessary to compare treated vs. untreated patients using systematic, sensitive and reproducible criteria.

Interventions

  • DEVICE Biopsy + Nerve Repair
  • PROCEDURE Biopsy Only

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-11-09
Est. Completion 2027-03
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03584022

The ClinicalTrials.gov registry entry for NCT03584022 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Biopsy + Nerve Repair is the first listed.

NCT03584022 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03584022 about?

NCT03584022 is a clinical study titled "Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial". This is safety study. Subjects will be undergoing the surgical procedure of nerve biopsy. After routine surgery without grafting, patients develop swelling, redness, tenderness and dysesthesia at the biopsy site. In order to determine whether grafting is safe compared to not repairing the nerve, it ...

What is the current status of trial NCT03584022?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2018-11-09. Estimated completion is 2027-03.

What conditions does trial NCT03584022 study?

This clinical trial studies the following conditions: Amyloidosis, Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Vasculitic Neuropathy (Disorder), Hereditary Neuropathy.

What interventions are being tested in trial NCT03584022?

The interventions under investigation include: Biopsy + Nerve Repair (DEVICE), Biopsy Only (PROCEDURE).

Who is sponsoring clinical trial NCT03584022?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03584022 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.